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E-mail: d.b@csic.esCystic fibrosis (CF) is the main genetic cause of death among
the Caucasian population. The disease is characterized by
abnormal fluid and electrolyte mobility across secretory
epithelia. The first manifestations occur within hours of birth
(meconium ileus), later extending to other organs, generally
affecting the respiratory tract. It is caused by mutations in
the cystic fibrosis transmembrane conductance regulator
(CFTR) gene.CFTR encodes a cyclic adenosinemonophosphate
(cAMP)-dependent, phosphorylation-regulated chloride chan-
nel required for transport of chloride and other ions through
cell membranes. There are more than 2,000 mutations
described in the CFTR gene, but one of them, phenylalanine
residue at amino acid position 508 (p.F508del), a recessive
allele, is responsible for the vast majority of CF cases world-
wide. Here, we present the results of the application of
genome-editing techniques to the restoration of CFTR activity
in p.F508del patient-derived induced pluripotent stem cells
(iPSCs). Gene-edited iPSCs were subsequently used to produce
intestinal organoids on which the physiological activity of the
restored gene was tested in forskolin-induced swelling tests.
The seamless restoration of the p.F508del mutation resulted
in normal expression of the mature CFTR glycoprotein, full
recovery of CFTR activity, and a normal response of the re-
paired organoids to treatment with two approved CF therapies:
VX-770 and VX-809.
INTRODUCTION
Cystic fibrosis (CF) is the most frequent genetic disease among the
Caucasian population, affecting ca. 90,000 individuals worldwide.
The first manifestations occur in early childhood and affect several or-
gans, resulting in defects in the pancreas, liver, intestine, vas deferens,
sweat ducts, and airways. The most severe and life-threatening conse-
quences of CF occur in the lung. Three decades ago, it was shown that
mutations in the cystic fibrosis transmembrane conductance regu-858 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2
This is an open access article under the CC BY-NC-ND license (httplator (CFTR) gene, inherited in an autosomal-recessive fashion,
are the underlying cause of CF disease1. More than 2,000 different
mutations have been described across the CFTR locus, but up to
date, only 346 genetic variants have been identified as pathogenic, dis-
ease-causing mutations (https://www.cftr2.org/). CFTR acts as an
anion channel at the apical surface of secretory epithelial tissues regu-
lating electrolyte and fluid transport across the plasma membrane.
Disruption of CFTR activity leads to acidification of luminal pH
and generation of a thick, sticky mucus at the affected epithelia.
Chronic pulmonary infections produced by bacterial colonization
of the abnormal mucus layer still represent the primary cause of mor-
tality. However, thanks to improved symptomatic treatments and
higher success rates in lung transplantations, CF is becoming a multi-
systemic disease affecting lung, intestine, pancreas, and liver.2
The deletion of the CTT triplet in exon 11 of the CFTR gene is the
most prevalent CF-causingmutation, representing 70% of all patients’
alleles.3 The resulting trafficking-deficient CFTR protein lacks the
phenylalanine residue at amino acid (aa) position 508 (p.F508del).
Despite tremendous efforts in the last years, there is still no cure for
all CF patients, including p.F508del patients4. Only two types of small
molecule treatments for p.F508del patients are presently available on
the market. Unfortunately, the strongest possible intervention, con-
sisting of a combination of both a potentiator to stimulate CFTR
channel activity (ivacaftor) and a corrector to promote CFTR traf-
ficking to the apical plasma membrane (tezacaftor or lumacaftor),
has only modest effects on patients’ lung function5,6. Most recently,
the US Food and Drug Administration (FDA) has approved a prom-
ising triple-combination therapy (ivacaftor-tezacaftor-elexacaftor)020 ª 2020 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgfor p.F508del patients, but the real benefit has yet to be fully evaluated
in the near future7,8. On the other hand, genetic-based therapies
hold the promise of a complete and definitive cure for the
disease, independently of the mutations carried by the patient, and
are considered “the most promising strategy to cure CF” by the Cystic
Fibrosis Foundation (https://www.cff.org/About-Us/Media-Center/
Press-Releases/Cystic-Fibrosis-Foundation-Launches-$500-Million-
Path-to-a-Cure/). It has been shown that either 6%–10% of corrected
cells9 in a treated epithelium or an overall 5% level of the normal
expression on the whole tissue10 is enough to restore wild-type func-
tionality. These numbers are well within the values achievable by
gene targeting and support the development of combined gene and
cellular therapies, like the ones being currently tested for other
diseases11,12.
Part of the slow progress in finding better treatments or even a cure
for the disease has been due to the lack of suitable in vitro models
that could recapitulate more closely the pathophysiology of the dis-
ease and the complexity of human organs, like lung, pancreas, liver,
and intestine. Several years ago Dekkers et al.13 developed a forsko-
lin-induced swelling (FIS) assay to monitor CFTR function in pri-
mary rectal-derived human intestinal organoids (HIOs), but the
fact that variation of swelling was observed among HIOs from
different CF individuals with identical CF-causing mutations indi-
cates that the FIS assay is sensitive to the effects of modifier genes,
an important issue in CF research14–16. Clearly, the results of the
FIS test would be more conclusive by establishing direct comparisons
between CF patient-derived organoids and, after gene correction of
the mutant allele, their isogenic counterparts. However, gene editing
of HIOs, although possible17, is difficult and subject to variability due
to possible multiple integration sites of the recombination vector or to
polyclonality of the edited organoids. Induced pluripotent stem cells
(iPSCs), on the other hand, offer the possibility of unlimited cell
expansion, generation of disease-affected cell lineages by directed dif-
ferentiation, and easy and accurate targeted gene correction.
Here, we present an integrative approach in which CF patient-derived
iPSC technology and seamless gene targeting, combined with a new
and robust method for the production of intestinal organoids from
iPSCs andFIS testing, provide a solid setting for the studyofCFTR func-
tion. Apart from their use in disease studies and drug discovery, isoge-
neic CFTR-repaired organoids could also serve as the basis for future
cell therapy applications, in which patients’ own cells are genetically
modified and used to regenerate damage organs. The current paper
demonstrates that this course of action is feasible in terms of restoring
the functionality of the treated cells. It also shows that it has the potential
to become the basis for an effective therapy, onceproper transplantation
protocols and regulatory guidelines are set in place.
RESULTS
Seamless Correction of the CFTR Gene by TALEN-Mediated
Homologous Recombination in CF iPSCs
To obtain a seamless correction of the p.F508del mutation in pa-
tient-derived CF-iPSCs, we devised a strategy based on Transcrip-Molecultion Activator-Like Effector Nuclease (TALEN)-mediated homolo-
gous recombination (HR), followed by the total removal of the
selection cassette with a piggyBac (PB) transposase system. This
approach guarantees the absence of any vector fragment in the pa-
tient’s genome after the whole procedure is completed. For this pur-
pose, we first designed a pair of TALENs that could recognize a
target site nearby the p.F508del mutation (Figure 1A). The speci-
ficity of the new TALENs was initially determined in K562 and
HeLa cell lines with the Surveyor nuclease assay. A high cleavage ef-
ficiency of about 50% confirmed their functionality in both cell types
(Figure S1). Then, a donor vector was designed containing a func-
tional allele of the CFTR gene. The genetic defect in p.F508del iPSCs
was corrected by introducing a CTT triplet in exon 11 of the CFTR
gene at the precise position where its absence causes the mutant
phenotype (Figure 1A). The targeting vector contains a trans-
poson-based, double-selection puromycin-(delta)thymidine kinase
(puroDtk) cassette driven by a phosphoglycerate kinase (PGK) pro-
moter and flanked by PB-specific inverted terminal repeat (ITR) se-
quences. Once the PB transposase recognizes those sites, it effi-
ciently catalyzes the seamless excision of the cassette. The
genomic TTAA sequence located in intron 11 at 126 bp downstream
of the 30 TALEN-binding site marks the PB recognition site for inte-
gration and excision of the transposon. Two CFTR recombination
arms (ca. 900 bp each) are present at both ends of the selection
cassette to promote homologous recombination in the proximity
of the p.F508del mutation. To prevent cutting of the targeting vector
or retargeting of the edited allele by TALENs, several silent muta-
tions were introduced into the 50 homology arm in close proximity
to the p.F508del deletion. In addition, a new BglII site was also
included to facilitate the screening of recombinant clones (Fig-
ure 1A). Although silent mutations do not modify the amino acid
sequence, they can introduce cryptic splice variants into the DNA
with deleterious effects on CFTR activity18. This possibility was
checked in silico with the Human Splicing Finder tool from Desmet
et al.19, and no cryptic site was found (data not shown).
Targeted repair of the p.F508del allele has been carried out on two
iPSC lines, independently derived in our lab from the same CF pa-
tient (IMEDEAi001-F)20. The deletion of the CTT triplet in the
targeted iPSC line was previously confirmed by PCR-directed
mutagenesis and MboI digestion21. CF iPSCs were nucleofected
with both TALEN plasmids and the donor vector at a ratio of
1:1:1 and seeded onto antibiotic-resistant feeders. Following
2 weeks of puromycin selection, resistant clones were isolated,
expanded, and analyzed by PCR. To identify positive clones,
both 50 and 30 ends of the recombination site were screened with
combinations of primers that bound to the selection cassette and
to genomic sites located outside the recombination arms (Fig-
ure 1A). Positive clones with the correct integration of the target-
ing construct were detected in both iPSC lines (Figures 1B and
1C). To eliminate possible recombination events 50 to the
p.F508del site that would give rise to the integration of the target-
ing construct into the CFTR locus, but without repairing the CTT
deletion, the 50 PCR products were digested with BglII. The newlyar Therapy: Methods & Clinical Development Vol. 17 June 2020 859
Figure 1. Seamless Correction of the p.F508del
CFTR Mutation by TALEN-Assisted HR in CF iPSCs
(A) Schematic representation of the footprint-free, TALEN-
mediated HR strategy for repairing the p.F508del muta-
tion. Target sequences of left and right TALENs, TTAA
piggyBac recognition site, as well as the CTT triplet
deletion are indicated on the genomic structure of the
p.F508del allele (blue). The targeting vector consisted of
two homology arms and a double-selection cassette
(rose). The corrective CTT and eight silent mutations (red)
are depicted on the 50 homology arm. Primers (black tri-
angles) and their respective PCR products (dashed lines)
used for HR screening are shown. (B) PCR screening of
puromycin-resistant representative iPSC clones from
L1 and L2 iPSC lines (upper panel). Candidate clones for
50 correction were confirmed by BglII digestion (lower
panel). C, negative control; C+, positive control. (C) PCR
screening of puromycin-resistant iPSC clones from L1
and L2 iPSC lines to detect correct 30 integration (upper
panel). piggyBac-mediated excision of the selection
cassette was confirmed in FIAU-resistant iPSC clones by
allele-specific PCR (lower panel). C, negative control;
C+, positive control. (D) Summary of HR efficiencies in
iPSC lines L1 and L2. (E) Sequence analysis of the edited
allele confirms p.F508del correction and the incorporation
of the eight silent mutations originally present in the
recombination cassette. The newly created BglII restric-
tion site is highlighted by a blue box. The amino acid
sequence of exon 11 is shown above the DNA sequence.
Underlined sequences indicate the binding sites of left (L)-
and right (R)-TALEN, respectively.
Molecular Therapy: Methods & Clinical Developmentgenerated BglII site is located at 28 bp 30 of the p.F508del site, so
that successful BglII digestion would very likely indicate the cor-
rect integration of the CTT triplet and therefore, the repair of
the gene. 71 clones identified as having undergone homologous
recombination were subjected to BglII analysis and all except
one (clone 111; Figure 1B) showed two bands of 1,019 and
306 bp, corresponding to the size of the fragments expected
from digesting the repaired allele (Figure 1B). The absence of BglII
digestion in clone 111 indicated that this clone lacked the BglII site
and very likely, the corrected CFTR sequence. This was most prob-
ably due to a recombination event that occurred 30 of the BglII re-
striction site. Overall, efficient HR-mediated integration was
confirmed in 60 out of 648 clones in CF iPSC line 1 (L1) and 10860 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020out of 98 analyzed clones in CF iPSC line 2
(L2), an overall correction efficiency of
approximately 10% (Figure 1D).
The next step of the procedure consisted of the
excision of the recombination cassette. For that
purpose, four recombined clones from L1 (L1-
27, L1-43, L1-65, L1-104) and five from L2 (L2-
18, L2-47, L2-61, L2-64, L2-87) were transfected
with the hyperactive PB transposase. Fialuridine
(20-deoxy-20-fluoro-b-D-arabinofuranosyl-5-iod-ouracil or FIAU)-resistant clones were isolated, expanded, and
analyzed by PCR with primers located outside the selection cassette.
To ensure specific amplification of the edited allele, the 50 primer
was designed to bind to the BglII restriction site. PCR screening
demonstrated the removal of the PB-based selection cassette in approx-
imately 53% of the analyzed clones in both previously edited CF iPSC
lines (Figure 1C).
After CFTR correction and cassette excision, one subclone from
L2-64 (L2-64.12) was randomly selected for further characteriza-
tion. A 2.2-kb DNA fragment spanning the complete genomic re-
gion involved in HR was amplified by PCR using primers P1 and
P4. PCR amplicons were cloned into the pGEM-T Easy Vector and
Figure 2. Molecular and Immunohistochemical
Characterization of the Corrected L2-64.12 iPSC
Line
(A) G-banding analysis showing a normal diploid karyo-
type. (B) PROGNOS prediction of CFTR and top 15
ranked potential off targets for the CFTR-specific TALEN
pair. Chromosomal localizations, type of genomic region,
closest gene, and observed cleavage (+) or its absence ()
are indicated for each potential off-target site. (C)
Expression of stemness markers SOX2, OCT4, NANOG,
and TRA-1-60 shown by immunofluorescence. Nuclei
were counterstained with DAPI (blue). Scale bar, 100 mm.
(D) Embryoid body formation by spontaneous differentia-
tion. Markers for the three germ layers: ectoderm (NES-
TIN, PAX6, TUJ1), mesoderm (GATA4, ACTININ, SMA),
and endoderm (SOX17, FOXA2, AFP). Nuclei were
counterstained with DAPI (blue). Scale bars, 100 mm.
www.moleculartherapy.orgsequenced. The detection of both wild-type and CFTR-repaired al-
leles confirmed CFTR repair in heterozygosity at the endogenous
CFTR locus. Figure 1E shows the edited sequence around the
p.F508del mutation site. The addition of the CTT triplet and the
presence of the eight silent mutations originally incorporated
into the targeting vector are highlighted. Alignment of the com-
plete sequenced region with a CFTR p.F508del template is shown
in Figure S2.
Characterization of CFTR-Corrected iPSCs
Once the presence of the corrected allele was verified, the repaired
CF iPSC line L2-64.12 was further characterized regarding genome
integrity, stemness, and pluripotency. G-banding analysis indi-
cated a normal diploid karyotype without chromosomal aberra-
tions (Figure 2A). To detect potential genomic imbalances at a
higher resolution, array comparative genomic hybridization
(aCGH) was performed by comparing on the one side the genomes
of repaired and nonrepaired CF iPSCs and on the other side the
genomes of repaired CF iPSCs and parental primary fibroblastsMolecular Therapy: Methods &(Figure S3). All in all, only five copy number
variations (CNVs) could be identified across
the genome. Although two CNVs emerged
during reprogramming and iPSC generation,
three CNVs were generated in the course of
HR-directed repair. The observed modifica-
tions could have their origin in the direct ac-
tivity of the genetic material added to the cells
or just be a consequence of having spent a
lengthy time in culture. To test possible off-
target effects of the TALENs in the L2-64.12
line, we decided to study the stability of the
loci predicted by the PROGNOS software as
the most likely affected by nonspecific TALEN
activity. CFTR, plus the top 15 sites ranked as
possible off-target regions were selected and
analyzed by the Surveyor assay (Figure 2B).All of the 15 predicted off-target sites were in intergenic or in-
tronic sequences. The analysis showed that the CFTR-specific
TALENs cut exclusively at the CFTR locus without any off-target
activity (Figure S4), suggesting that the three CNVs detected dur-
ing HR-directed repair most probably were not originated during
the TALEN-mediated correction process per se but rather, were
the consequence of prolonged in vitro cell culture.
Stemness of the repaired iPSC line was then tested by immunofluo-
rescent analysis with a panel of diagnostic antibodies: aSOX2,
aOCT4, aNANOG, and aTRA-1-60 (Figure 2C). In all cases, the
corresponding antigens were strongly expressed, indicating that
the L2-64.12 line had maintained its stem cell properties during
the repair process. Human pluripotent stem cells have the capacity
to differentiate into three embryonic germ layers: ectoderm, meso-
derm, and endoderm. To test whether our newly corrected iPSC
clone L2-64.12 retained this ability, embryoid bodies (EBs) were
produced, plated on gelatin-coated dishes for 20 days, and analyzed
by immunostaining. The presence of ectodermal lineages wasClinical Development Vol. 17 June 2020 861
Figure 3. Directed Differentiation of CFTR-Corrected L2-64.12 iPSCs
toward Human Intestinal Organoids
(A) Following 3 days of ACTIVIN-A/WNT3A treatment, CFTR-repaired iPSCs show
expression of DE markers FOXA2 (green), GATA4 (red), and SOX17 (green). Scale
bar, 50 mm. (B) Definitive endodermal cells were further differentiated into HGE
(8 days) by additional exposure to theWNT3A agonist CHIR99021 for 5 days. At that
point the cells expressed the hindgut marker CDX2 (green) and were completely
negative for the anterior foregut markers FOXA2 (green) and SOX2 (red). Scale bar,
50 mm. (C) Generation of iPSC-derived intestinal organoids from the p.F508del
mutant (L2) and corrected iPSCs (L2-64.12) in the absence of mesenchymal cells.
Scale bars, 100 mm. (D) Immunostaining of CFTR-repaired HIO for the intestinal
markers CDX2 (red), SOX9 (green), E-CAD (red), and VILLIN (green). Scale bars,
50 mm. Nuclei were counterstained with DAPI (blue) (A, B, and D).
Molecular Therapy: Methods & Clinical Developmentconfirmed by the expression of NESTIN, Paired box protein 6
(PAX6), and Neuron-specific class III beta-tubulin (TUJ1), whereas
GATA Binding Protein 4 (GATA4), a-ACTININ, and smooth mus-
cle actin (SMA) illustrated the formation of mesoderm and Tran-862 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2scription factor SOX-17 (SOX17), Hepatocyte nuclear factor 3-
beta (FOXA2), and a-fetoprotein (AFP) of endoderm (Figure 2D).
Directed Differentiation of the CFTR Mutant and Corrected
iPSCs toward CFTR-Expressing Intestinal Organoids
Native CFTR is expressed in multiple organs, such as lungs, pancreas,
liver, and gastrointestinal tract. iPSC differentiation toward lung
epithelial cells is very complex and shows high variability in differenti-
ation efficiencies22. Recently, it has been demonstrated that CFTR-ex-
pressing HIOs, derived from rectal biopsies, could be used to monitor
CFTR function in a robust assay with a simple readout13. Based on this
observation, we have developed a novel, stepwise, three-dimensional
(3D) differentiation protocol to generate HIOs from iPSC (manuscript
in preparation). Intestinal organoids, produced according to the new
protocol, were used to study the restoration of CFTR function after
HR-directed CFTR repair. During development, the first precursor of
intestinal epithelium to appear is the multipotent definitive endoderm
(DE). Thus, CF-corrected iPSCs were initially differentiated in vitro
into DE by treating them with the signaling molecules ACTIVIN-A
and Wingless-Type MMTV integration site family, member 3A
(WNT3A)23,24. In order to ensure high differentiation frequencies,
we incorporated a DMSO (dimethylsulfoxide) pretreatment step in
our differentiation protocol prior to DE generation25. DE cells at day
3 of differentiation showed a typical expression pattern of endoderm
transcription factors, such as FOXA2, SOX17, andGATA4 (Figure 3A).
The activation of endodermal markers was accompanied by the down-
regulation of the pluripotent stem cell markers OCT4 and NANOG
(data not shown). The efficiency of DE derivation from CF-corrected
iPSCs was about 80%. The next differentiation step consisted of the
production of hindgut endoderm (HGE), the direct precursor popula-
tion of the more posterior digestive tract. Exposure to high concentra-
tion of WNT3A agonists for 5 days resulted in the formation of HGE
lineages with the propensity to differentiate into intestinal epithelial
cells26,27. A large percentage of HGE cells expressed the hindgutmarker
Caudal Type Homeobox 2 (CDX2), whereas the generation of the ante-
rior foregut lineage was completely blocked, as demonstrated by the
lack of FOXA2/SOX2 coexpression (Figure 3B). At that point, floating
3DHGE spheroids were embedded intoMatrigel drops and cultured in
the presence of intestinal growth factors. The sequential maturation of
the hindgut spheroids into mature intestinal organoids could be
observed during the following weeks. The resulting HIOs contained
crypt-like structures and an internal lumen lined by columnar epithe-
lium, closely resembling the morphology of native intestinal tissue.
AlthoughHIOs expressed intestinal markers, such as Kruppel Like Fac-
tor 5 (KLF5), CDX2, and VILLIN, all attempts made at this point to
detect restoration of CFTR function by the FIS assay in CFTR-cor-
rected, iPSC-derived HIOs failed (data not shown). This suggested
very low to undetectable levels of CFTR expression that could be ex-
plained either by the failure in restoring the CFTR gene or by an incom-
plete maturation of the organoids.
The functionality of the FIS assay has been demonstrated in primary
HIO obtained by crypt isolation during rectal biopsies28, but not in
iPSC-derived organoids. We, therefore, introduced several020
Figure 4. Restoration of CFTR Protein Expression in Human Intestinal
Organoids Derived from CFTR-Corrected iPSCs
(A) Western blot analysis. C band, mature, complex glycosylated CFTR; B band,
immature CFTR. Calu-3 cells and primary rectal wild-type organoids (HUBWT) serve
as positive control for the detection of the mature CFTR C band, whereas primary
rectal CFTR p.F508del homozygous organoids (HUB 508/508) only express the
immature B band of the CFTR protein. HIO L2 and HIO L2-64.12 intestinal organoids
derived from mutant and corrected CF iPSCs, respectively. Note the inverse ratio
between the immature and glycosylated forms of CFTR in the two types of organoids.
a-tubulin is the protein-loading internal control. (B) Immunofluorescence analysis of
CFTR expression. No CFTR protein is detected in iPSC-derived CFTR p.F508del
homozygous HIOs (top row). Colocalization of CFTR (red) with Villin (green) but not
with the basolateral marker E-cadherin (green/purple) at the apical surface in CFTR-
corrected HIOs (middle and bottom rows). Nuclei were counterstained with DAPI
(blue). Scale bars, 50 mm (top and middle rows); scale bar, 20 mm (bottom row).
www.moleculartherapy.orgmodifications to the maturation step of the original differentiation
protocol in order to generate iPSC-derived HIOs that more closely
resembled biopsy HIOs (Figure 3C; manuscript in preparation).
HIOs derived from CFTR-corrected and mutant iPSCs following
this new protocol were able to grow without support of the mesen-
chymal layer that is normally found in iPSC-derived HIO cultures
(Figure 3C). In addition, the growth rate was very similar to that
observed in biopsy-derived HIOs29. The intestinal phenotype of
iPSC-derived HIOs was confirmed by immunostaining, showing
the expression of the intestinal transcription factors SOX9 and
CDX2, as well as the detection of the enterocyte marker VILLIN.
The epithelial origin of HIOs was confirmed by positive E-cadherin
(E-CAD) staining (Figure 3D). Successful differentiation of the orig-
inal CF mutant iPSC line, L2, into intestinal organoids was equally
verified by immunofluorescence studies at DE, HGE, and HIO
stages (Figure S5). Most importantly, CFTR protein expression, a
prerequisite for the recovery of CFTR activity, was detected mainlyMoleculas the complex-glycosylated form (C band) in CFTR-corrected
HIOs, whereas only immature, core-glycosylated CFTR (B band)
was expressed in mutant HIOs (Figure 4A). The CFTR expression
pattern was similar to healthy and p.F508del primary HIOs, respec-
tively. Moreover, corrected CFTR protein was found to be expressed
on the apical membrane that lines the inner lumen of HIOs, as evi-
denced by colocalization of CFTR and the apical marker VILLIN
(Figure 4B).Functional Restoration of CFTR Channel Activity in iPSC-
Derived, CFTR-Corrected Intestinal Organoids
To determine whether heterozygous CFTR repair of the p.F508del
allele could support functional recovery of CFTR channel activity,
we first tested if CFTR activation by forskolin-induced elevation of cy-
clic AMP (cAMP) levels was able to induce fluid influx into the orga-
noid’s lumen, thus augmenting their surface area.
To allow quantification of organoid expansion in the course of FIS
assays, corrected and mutant HIOs were previously labeled with cal-
cein green, a cell-permeant dye that exclusively marks living cells.
Upon 180 min of forskolin treatment, CFTR-corrected and mutant
HIOs increased their surface area to 177% (±9 SD) and 103% (±1
SD), respectively (Figures 5A–5C), where 100% represents the orig-
inal surface prior to treatment. These expansion rates are in good
concordance with previous findings, where primary wild-type and
p.F508del mutant HIOs were used in FIS assays over a period of
60 min13. FIS response in human organoids was reported to be
entirely dependent on CFTR function13, so to demonstrate CFTR
dependency in our iPSC-derived HIO culture system, iPSC-derived
organoids were pretreated for 16 h, with the specific CFTR inhibitor
CFTRinh-172
30, before starting the FIS assay. In fact, forskolin-
induced expansion in CFTR-corrected HIOs was completely
blocked in the presence of CFTRinh-172 (102% ± 2% SD; Figures
5A and 5C), whereas as expected, the negligible FIS response in
CFTRmutant HIOs did not significantly change (96% ± 1% SD; Fig-
ures 5A and 5B). This inhibition was reversible after washing out
CFTRinh-172
31 (data not shown).
To examine whether functional rescue of p.F508del mutant CFTR is
feasible with a combined treatment of chemical CFTR modulators,
we treated iPSC-derived HIOs simultaneously with the CFTR potenti-
ator (VX-770) and the corrector (VX-809; preincubated for 16 h). The
double treatment markedly increased the FIS response in p.F508del
mutant HIOs (swelling rate: 133% ± 7% SD; Figures 5A and 5B), albeit
to a lesser extent than what was observed in CFTR-corrected HIOs
without VX-770/VX-809 treatment, suggesting that HR-directed
CFTR repair is considerably more efficient in restoring CFTR function
than the clinically approved double treatment VX-770/VX-809
(Orkambi). CFTR-corrected HIOs showed an even higher increase in
surface area (206% ± 14% SD; Figures 5A and 5C) when treated with
VX-770/VX-809, thus validating the impact of CFTR modulators on
CFTR function in CF-corrected HIOs. Finally, organoid swelling was
completely abolished in VX-770/VX-809-treated, CFTR-correctedar Therapy: Methods & Clinical Development Vol. 17 June 2020 863
Figure 5. Functional Recovery of CFTR Activity in
iPSC-Derived, CFTR-Corrected Human Intestinal
Organoids
(A) Representative fluorescence live-cell microscopy im-
ages of calcein green-labeled, CFTR-corrected and
p.F508del mutant HIOs following 5 mM forskolin treatment,
alone or in combination with pharmacological CFTR
modulators for 60 min. Scale bars, 100 mm. (B and C)
Normalized forskolin-induced swelling of p.F508del (B) and
CFTR-corrected (C) mutant organoids upon CFTR inhibi-
tion (CFTRinh-172) and/or activation (VX-770/VX-809) for
180 min. Surface areas are calculated as percentages
(mean ± SEM) relative to that at t = 0 (100%). DMSO
treatment serves as negative control. (A–C) Organoids were
pretreated for 16 hwith 50 mMCFTRinh-172 (CFTR inhibitor)
and/or 3 mM VX-809 (CFTR corrector). CFTR potentiator
VX-770 (3 mM) was added simultaneously with forskolin.
Molecular Therapy: Methods & Clinical Development(104%± 6% SD) andmutant (99%± 2% SD)HIOswhenCFTR activity
was blocked by CFTRinh-172 exposure (Figures 5A–5C).
Taken together, these results strongly indicate that heterozygous
CFTR correction by TALEN-mediated footprint-free gene targeting
resulted in full restoration of CFTR function in iPSC-derived HIOs,
a result compatible with similar observations made on iPSC-derived,
2D-cultured epithelial cells32.
DISCUSSION
Here, we describe the correction, by gene targeting in patient-derived
iPSCs, of the CFTR p.F508del mutation. Gene-editing protocols are
often associated with undesired and potentially harmful modifica-
tions of the genome; to minimize the possibility of this type of events,
a strategy based on an antibiotic selection step, followed by a triple se-
rial DNA screening, was devised. In addition, a new procedure to864 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020obtain intestinal organoids from iPSC-edited
cells was validated, and the complete functional
restoration of CFTR activity in CF-corrected,
iPSC-derived intestinal organoids demonstrated
using the CFTR-dependent FIS assay.
After transfection, antibiotic selection eliminated all
cellular clones in which the antibiotic-resistant
cassette had not been incorporated into the
genome. The first PCR screening step was designed
to identify cellular clones with HR-driven integra-
tion of the selection cassette into the targeted locus.
Validation at both 50 and30 recombination siteswas
necessary to avoid false positives due to the frag-
mentary integration of the recombination cassette.
The second screening exploited a newly created, si-
lent BglII restriction site. Due to its close proximity
to the p.F508del mutation, successful digestion of
the amplicon comprising the site was indicative of
a very likely, correct cointegration of the restoringCTT triplet. Finally, the third screening step was carried out to confirm
piggyBac-catalyzed excision of the selection cassette and therefore, a
seamless repair of theCFTRgene.Due to the silentmutations introduced
into the recombination cassette, allele-specific PCRs could be performed
to identify recombinant CF-repaired clones in which the selection
cassette had been properly cut out by PB transposase.
Our TALEN-mediated HR approach resulted in the correction of the
p.F508del mutation in two iPSC lines derived from one CF patient
with efficiencies between 9.3% and 10.2%. These efficiencies are supe-
rior or similar to correction rates reported in other nuclease-assisted,
genome-editing studies, where the p.F508del mutation has been re-
paired33–36. It should be noted that the efficiency of HR-driven
correction depends onmany factors, such as cell type, cell line, cutting
efficiency of designer nuclease, nuclease retargeting, proximity of the
double-strand breaks to the repair site, sequence identity between
www.moleculartherapy.orgdonor template and target region, as well as the type of homology-
directed repair (HDR) template37. For instance, Lee et al.34 reported
an overall repair efficiency of <1% in a CF lung epithelial cell line.
This low level of repair was most probably due to the long distance
(203 bp) between the p.F508del mutation and the Zinc Finger
Nuclease (ZFN) target site, as well as to sequence variation between
donor plasmid and target region. Another study used short DNA
fragments and TALENs to correct the CTT deletion in CF iPSCs,
with correction rates as low as 0.1%, although the efficiency increased
up to 10% after six cycles of enrichment of the recombinant cells36.
More recently, two other studies claimed to have obtained higher
HR-driven repair efficiencies at the p.F508del locus by employing
CRISPR/Cas9-mediated, gene-editing approaches in combination
with a donor vector33 or single-stranded oligodeoxynucleotides
(ssODNs)35 as repair templates. In the first study, editing efficiency
of 16.7% was observed in a CF iPSC line, whereas the correction
rate in the second study ranged from 2.5% to 22%, depending on
the cell type used. Although higher HR rates can be achieved by elec-
troporating CRISPR/Cas9 as a recombinant ribonucleoprotein35, we
have opted to utilize the TALEN technology to enhance CF gene
correction in iPSCs, since the CRISPR/Cas9 system, in spite of recent
efforts to minimize off targeting, seems still to be associated with
increased off-target effects38,39. On the contrary, TALENs generally
show a higher level of specificity, which relies on their ability to recog-
nize longer target sequences (30–36 bp)40, the limitations imposed by
the required distance between target sequences41 and on the fact that
they only act if both members of the pair bind to the target sequence
on opposite strands.
Although small DNA fragments, including ssODNs, are nowadays
widely used for HR-based gene correction of small fragments, such
as single-base pair mutations, like the CTT deletion in the CFTR
gene,35,36,42 this elegant and drug selection-free approachmight require
laborious screening analysis in order to identify targeted clones43.
Additional, more serious disadvantages of ssODN-based gene editing
are the generation of indel mutations at HR sites by the microhomol-
ogy-mediated end-joining mechanism44 and the random insertion of
ssODN throughout the genome with a frequency of up to 18%45. A
recent study by Vaidyanathan et al.46 has reported recombination fre-
quencies of around 40% at the CFTR locus in upper-airway basal stem
cells from CF patients. They achieved this mark by adeno-associated
virus (AAV) transduction of CRISPR/Cas9 and ssODNs. However,
the results should be considered in light of new evidence suggesting
the possibility of undesired rearrangements produced by ssODNs,
both at the target site and at distant locations47,48. In addition, therapies
based on viral vectors, including AAVs, might generate immune re-
sponses against the virus and are not applicable to individuals with pre-
existing neutralizing antibodies49. For all of these reasons and despite
the attractiveness of the ssODN-mediatedHR system, we opted instead
for an ex vivo PB transposon-based gene-targeting strategy. Similar to
previous reports33,50, we obtained integration-free-corrected iPSC
clones with an excision efficiency of the drug-resistant cassette of
53% on already-selected edited iPSC lines. In several CFTR gene-tar-
geting studies, seamless correction of the p.F508del allele was not em-Moleculployed, thereby leaving behind donor DNA remnants, such as the com-
plete selection cassette17,34 or a residual loxP site after Causes
Recombination enzyme (CRE)-mediated excision of the donor vec-
tor32, in the genome of repaired CF iPSCs. iPSCs harboring those un-
wanted genetic modifications have a limited application, not only in
clinical settings but also for disease modeling in basic research and
drug-screening programs.
Functional restoration of CFTR channel activity after gene editing has
been previously demonstrated in iPSC-derived epithelial cells by us-
ing 2D differentiation monolayer systems32,33,36,42. However, due to
variable differentiation efficiencies, iPSC differentiation often resulted
in the derivation of heterogeneous populations in terms of CFTR
expression, thereby impeding unambiguous readouts during func-
tional assays. We, therefore, developed a novel iPSC-derived 3D orga-
noid model that allows the precise assessment of CFTR activity in
CFTR mutant and repaired HIOs by the FIS assay. Importantly, the
readout of this technique has been shown to be completely dependent
on CFTR in primary HIO13, thus serving as an ideal method to mea-
sure the recovery of CFTR function following CFTR gene correction.
Before starting the FIS assay, CFTR expression and its localization at
the plasma membrane were confirmed in CFTR-corrected HIOs by
immunostaining. In addition, detection of mature, complex, glycosy-
lated CFTR protein by western blot strongly indicated the restoration
of correct CFTR processing upon CFTR gene repair and a very likely
functional recovery of the gene, since only this processed form of
CFTR is able to reach the plasma membrane and exert its function
as an anion channel. On the contrary, p.F508del mutant HIOs only
expressed the immature core-glycosylated form of CFTR that is
rapidly degraded in the endoplasmic reticulum (ER) before reaching
the plasma membrane. These results are in concordance with recent
findings showing the localization of mature CFTR at the plasma
membrane in primary wild-type but not in p.F508del homozygous
HIOs13.
Finally, functional testing of CFTR protein activity in FIS assays
demonstrated that p.F508del correction in one of the two mutant al-
leles is enough for the complete rescue of CFTR function, as indicated
by similar levels of organoid swelling to those observed in wild-type13
or CFTR-corrected, primary HIOs17. Interestingly, heterozygous gene
correction seems to be far more efficient in terms of restoring CFTR
activity than the combinatorial treatment of homozygous p.F508del
samples with the CFTR potentiator (VX-770) and corrector (VX-
809) together, which is consistent with a previous report using pri-
mary HIOs17. It has been described that CF patients harboring
p.F508del in homozygosity differ significantly in their response to
Orkambi (VX-770/VX-809) treatment, suggesting that the CF patient
in our study could belong to the low responder group6,51. Patient-spe-
cific differences were also observed in primary HIOs with identical
CF-causing mutations, further indicating that individual genetic
background, in addition to CFTR status, might affect the degree of
FIS response in vitro and successful therapy in vivo14,15. Given the in-
fluence of genetic modifiers on CFTR functional tests and more
importantly, on the course of the disease and the response of patientsar Therapy: Methods & Clinical Development Vol. 17 June 2020 865
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terparts represent an optimal isogenic platform to use in disease
modeling and drug screening. Although previous gene-targeting
studies have validated the restoration of CFTR activity in iPSC-
derived lung epithelial cells using a variety of techniques, such as Us-
sing chamber32,36. whole-cell patch-clamp33 and iodide efflux as-
says32, the combination of the HIO and FIS assay is presumably the
easiest and most robust way to validate CFTR activity in a complex,
polytypic tissue model. In addition, the possibility of expanding
iPSC-derived HIOs to an unlimited number, thanks to the mainte-
nance of an intestinal stem-cell subpopulation, makes it very attrac-
tive for high-throughput screening in 384-well plates when combined
with automated live microscopy. Indeed, pharmaceutical companies
have already started to integrate intestinal organoids in their drug-
discovery pipeline28. It is important to keep in mind, however, that
until exhaustive comparisons are performed, it cannot formally be
ruled out that drug responses of certain CFTR variants can vary in
a tissue-specific manner due to the recruitment of different cis-regu-
latory elements nearby or within the CFTR locus. In this regard, it has
been demonstrated that CFTR expression is differentially regulated in
lung and intestinal cells through cell type-specific enhancer elements
that are located in intergenic and intronic regions18.
In summary, this report demonstrates, to our knowledge, for the first
time, the integration of an efficient method for seamless CFTR correc-
tion in CF patient-derived iPSCs with a functional intestinal organoid
swelling test to determine the biological activity of the resulting protein.
The linkage of the two methods was made possible by a novel and effi-
cient protocol for the production of intestinal organoids from edited
iPSCs. The association of these three procedures: disease or patient-
specific iPSC production, gene editing, and organoid-based functional
testing, together with improved protocols for the reintroduction the
targeted cells into the patients4, will have a profound impact, not
only in studying the pathophysiology of CF and other human diseases
but also in more accurate drug-discovery protocols and personalized
medicine applications in the future, thus providing an alternative to
other gene-therapy approaches being currently tested on CF4,52.
MATERIALS AND METHODS
Cells and Culture Procedures
For gene-targeting experiments, we used an iPSC line (IMEDEAi001-
F) recently generated in our lab from a CF patient20. Human iPSCs
were cultured in KnockOut DMEM (Invitrogen, USA), supplemented
with 20% KnockOut Serum Replacement (KOSR; Invitrogen, USA),
2 mMGlutaMAX, 0.1 mM b-mercaptoethanol, 1% nonessential amino
acid (NEAA; Invitrogen, USA), and 10 ng/mL basic fibroblast growth
factor (bFGF; PeproTech, UK). iPSC passage was carried out using re-
combinant trypsin (TrypLE Select; Invitrogen, USA) and the final addi-
tion of 10mMrho-associated protein kinase (ROCK) inhibitor Y-27632
(Sigma, Spain). Mature, intestinal iPSC-derived organoids and rectal
organoids were maintained in intestinal growth media and passed
1:3 to 1:6 every 5–8 days, as described previously53,54. HUB wild-type
and HUB p.F508del homozygous rectal organoid lines were purchased
from Hubrecht Organoid Technology (https://hub4organoids.eu/).866 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2Generation of CFTR-Specific TALENs andDetection of Nuclease
Activity
TALEN expression vectors designed to target and cleave 55–57 bp 30
of the p.F508del mutation, were synthesized by Transposagen (USA).
The length of the recognition sequence of each TALEN is 17 bp (left
binding site: 50-ACAGAAGCGTCATCAAA-30; right binding site:
50-AGGTAAGAAACTATGTG-30) and is separated by a 16-bp
spacer. The expression of the TALEN genes is under control of the
cytomegalovirus (CMV) promoter.
The cleavage activity of the newly generated CFTR TALENs was
analyzed in two highly transfectable cell lines, K562 and HeLa. 1 
106 K562 and HeLa cells were transiently transfected with 2 mg of
each TALEN vector for 48 h. Genomic DNA from the TALEN-trans-
fected cell populations was isolated and the target site amplified by
PCR using the ZFN-forward (Fw)/P6 primers (see Table S1). To
assess the frequency of indels generated after cleavage by TALENs,
the Surveyor nuclease assay (Integrated DNA Technologies [IDT],
Belgium) was used. For this purpose, PCR amplicons were denatured
and slowly reannealed. Resulting heteroduplexes were cleaved by the
Surveyor nuclease, whereas homoduplexes were left intact. The het-
erogeneous DNA population was run on a microchip device (Bio-
analyzer 2100; Agilent, USA), and the efficiency of TALEN cleavage
(percentage of indels) was quantified by densitometry as a ratio be-
tween cleaved and noncleaved DNA bands.
Targeting Vector Design
Two vectors were produced. The first one (Seq_1) was designed to be
used, prior to gene-targeting experiments, as a template to optimize
the PCR reactions used in the screening for recombinant clones.
For this purpose, specific genomic regions, immediately adjacent
but external to the 50 and 30 recombination arms, were added to the
vector to allow primer binding. The length of the 50 and 30 homology
arms was 916 and 920 bp, respectively. In order to prevent retargeting
of the recombined allele by TALENs, five silent point mutations were
introduced into the 50 recombination arm. In addition, a new silent
BglII restriction site was also created to facilitate the detection of re-
combinant clones by PCR, followed by digestion of the amplification
product with the enzyme (Figure 1A). Primers specific for the recom-
binant allele were also designed (Table S1). The final targeting vector,
pMC3.1, was obtained by modifying Seq_1 in three cloning steps. The
elimination of the external primer-binding regions attached to the ho-
mology arms was performed by EcoRI and MluI digestions. Finally,
the double-selection cassette PB:PGKpuroDtk from pMCS-AAT-
PB:PGKpuroDtk55 was cloned via NheI/NotI digestion/ligation in be-
tween the homology arms. The pMCS-AAT-PB:PGKpuroDtk
plasmid was provided by the Sanger Institute under a Material Trans-
fer Agreement (MTA).
Electroporation of iPSCs
Nucleofection was performed with the P3 Primary Cell 4D-Nucleo-
fector Kit (Lonza, Walkersville, MD, USA), according to the manu-
facturer’s instructions. To avoid feeder cell contamination, iPSCs
were expanded in Matrigel-coated p100 culture plates prior to020
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(Gibco, USA), centrifuged at 200  g, and resuspended in nucleofec-
tion buffer 3. For homologous recombination experiments, 2 mg of
TALEN and donor plasmids were transfected per 1  106 cells in a
100-mL cuvette using the CB-150 program. In piggyBac excision ex-
periments, 5 mg of piggyBac transposase (pCMV-HAhyPBase) per
million cells was employed in nucleofection assays. Nucleofected
iPSCs were seeded in the presence of 10 mM ROCK inhibitor onto
irradiated HAF-1/W3R puromycin-resistant feeder cells, kindly pro-
vided by Dr. Chen from Johns Hopkins University School of Medi-
cine (Baltimore, MD, USA).56
Isolation of Recombined Clones and PCR Screening
After selection with 1 mg/mL puromycin (Sigma, Spain) or 250 nM
FIAU (Sigma, Spain) for 12–18 days, individual resistant colonies
were manually picked and transferred to 48-well plates previously
seeded with irradiated feeder cells. After 7–10 days, iPSC clones were
trypsinized (TrypLE) and duplicated in either Matrigel-coated or
feeder cell-containing 48-well plates. Genomic DNA was extracted
from clones grown in feeder-free, Matrigel-coated plates using a stan-
dard protocol, whereas clones grown on irradiated feeders were main-
tained and later expanded in the case of successful recombination.
Shortly, genomic DNA from 48-well plates was isolated by proteinase
K digestion overnight (O.N.) at 55C, precipitation of DNA with iso-
propanol, washing with 70% ethanol, and resuspension in Tris-
EDTA buffer. The first round of the screening consisted of the identi-
fication of recombinant clones. For this purpose, both 50 and 30 ends of
the recombination site were analyzed by PCR. One primer of each
primer pair was located in the genomic region outside the correspond-
ing recombination arm; the other one was situated within the selection
cassette (P1/P2 and P3/P4 pairs; Table S1). To confirm positive recom-
binant clones, the amplicons generated by 50 PCR were subsequently
digested with BglII. The absence of random integration of the recom-
bination cassette into the genome was verified by PCR using primers
specific for the selection cassette (Reint-Fw/Reint-Rv); Table S1).
Excision of Recombination Cassette by piggyBac Transposase
Following the identification of corrected clones, the selection cassette
was removed by nucleofection of 5 mg of pCMV-HAhyPBase per 1
106 iPSCs. Selection with FIAU (250 nM) was started 24 h after nu-
cleofection and resistant clones picked, expanded, and duplicated,
as described above. To identify clones with successful excision of
the selection cassette, the correct size of the CFTR target site was
confirmed by PCR using primers specific for the edited allele (P5/
P6; Table S1).
Sequencing
Genomic DNA from donor cells was isolated, as described above. For
sequencing, a 2,250-bp long fragment comprising the whole CFTR-
targeted area, including the p.F508del mutation site, was amplified
by PCR with the P1 and P4 primers (Table S1). PCR products were
cleaned using the Zymoclean Gel DNA Recovery Kit (Zymo
Research, CA, USA) and subcloned into the pGEM-T Easy Vector,
according to the manufacturer’s recommendations (Promega,MoleculUSA). Sequencing of the CFTR alleles was performed by Secugen
(Madrid, Spain) using the same amplification primers.
Prediction and Analysis of Off-Target Sites
Prediction of potential off-target sites after p.F508del correction was
done with PROGNOS software fromDr. Gang Bao’s laboratory.57 Pa-
rameters, such as targeted region and repeat variable domains (RVDs)
for both TALENs as well as variable length of spacer (10–30 bp), were
introduced to predict off-target sequences throughout the genome.
The 16 most likely candidates were PCR amplified in the CFTR-cor-
rected clone using primers designed by PROGNOS (Table S1). Sub-
sequently, the amplicons were analyzed by the Surveyor nuclease
assay (IDT, Belgium), as previously described.
Generation of Embryoid Bodies
To produce EBs, iPSC colonies were mechanically collected and
transferred into a 15-mL conical tube. Once the colonies settled at
the bottom of the tube, media were discarded, and iPSCs were
cultured in bacteriological Petri dishes with DMEM plus 10% fetal
bovine serum (FBS), 1% nonessential amino acids, and 2 mM Gluta-
MAX for 10 days. Cavitation was then assessed and EBs mechanically
disrupted and plated onto gelatin-coated, 24-well plates. Media were
changed twice weekly, and after 10–20 days of spontaneous differen-
tiation, cells were used for immunofluorescence studies.
Differentiation toward HIOs
iPSCs were harvested by trypsinization and replated for 1 h on
gelatin-coated dishes to induce the depletion of human fibroblast
feeders. Then, the nonadhered iPSC suspension was centrifuged; re-
suspended in iPSC growth media, supplemented with 10 mM Y-
27632; and plated on tissue-culture plates (100,000 cells/cm2), previ-
ously coated with growth factor-reduced Matrigel (BD Biosciences,
Spain). To improve differentiation efficiency, cells were treated on
the following day with 1% DMSO (Sigma, Spain) for 24 h.25 Subse-
quently, differentiation into definitive endoderm was performed, as
previously described, with slight modifications23. Briefly, cells were
washed three times with PBS (Biowest, France) and cultured in
RPMI 1640, supplemented with GlutaMAX (2 mM; Life Technolo-
gies, USA), 1% NEAA (Life Technologies, USA), 1% penicillin/strep-
tomycin (Life Technologies, USA), 0.2% FBS (Biowest, France),
100 ng/ml human activin A (R&D Systems, UK), and 25 ng/mL
WNT3A (R&D Systems, UK). Following 24 h of endoderm differen-
tiation, WNT3A was withdrawn, and cells were differentiated only in
the presence of activin A. At day 2 of endoderm induction, FBS con-
centration was shifted to 2%.
For hindgut specification, early definitive endodermal cells from day 3
were exposed to high doses of WNT3A. Briefly, cells were washed
twice with basal differentiation media (Biowest, France) and cultured
in RPMI 1640, supplemented with 1xB27, GlutaMAX (2 mM; Life
Technologies, USA), 1% NEAA (Life Technologies, USA), 1% peni-
cillin/streptomycin (Life Technologies, USA), 2% FBS (Biowest,
France), and 6 mM CHIR99021 (STEMCELL Technologies, France)
for 5 days. Floating 3D hindgut spheroids were embedded in thear Therapy: Methods & Clinical Development Vol. 17 June 2020 867
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R-spondin1, Noggin, epidermal growth factor (EGF), and WNT3A
(PeproTech, UK) to allow further intestinal maturation.26 Finally, a
novel differentiation protocol was employed to generate intestinal or-
ganoids that were able to grow without a mesenchymal niche (manu-
script in preparation), thus facilitating their use in FIS assays.
FIS Assay
FIS assays were performed as recently described53 but withminormod-
ifications. Briefly, human iPSC-derived intestinal organoids from a 5-
to 7-day-old culture were harvested, mechanically broken by pipetting,
resuspended inMatrigel, seeded as 4 mL drops in a 96-well culture plate
(Nunc), and cultured for 24 h in intestinal growth media. Each drop
contained approximately 40–80 organoids. 50 mM CFTRinh-172
(Sigma, Spain) and 3 mMVX-809 (SelleckChemicals, USA)were added
tomedia after seeding for CFTR inhibition and correction, respectively.
After 16 h pretreatment and following preincubation for 30 min with
5 mM calcein green (Invitrogen, USA), organoids were exposed to
5 mM forskolin and analyzed with a fluorescent microscope (Leica
DMI6000B, objective 5) in vivo. Each experimental condition was
measured in triplicate and during 180 min. In the case of CFTR poten-
tiation, 3 mM VX-770 (Selleck Chemicals, USA) was added simulta-
neously with forskolin. Forskolin-induced organoid swelling relative
to time (t) = 0 (100%) of forskolin treatment was quantified by image
processing using ImageJ software (NIH), and an increase of total orga-
noid area over time was calculated from triplicates.
Immunofluorescence
Undifferentiated iPSCs, differentiated cells, and iPSC-derived orga-
noids were washed with PBS, fixed for 20 min with 4% paraformalde-
hyde, and washed again with PBS. Immunocytochemistry was per-
formed for Nanog (1:150, rabbit immunoglobulin [Ig]G polyclonal;
Abcam, Spain), Oct4 (1:100, rabbit IgG polyclonal; Santa Cruz
Biotechnology, USA), Tra-1-60 (1:100, mouse IgM; Millipore,
USA), AFP (1:100, rabbit IgG; Dako, Denmark), Nestin (1:500, rabbit
IgG; Sigma, Spain), Tuj1 (1:500, rabbit IgG; Covance, UK), Sox17
(1:100, goat IgG; R&D Systems, UK), a-actinin (1:200, mouse IgM;
Sigma, Spain), SMA (1:200, mouse; Sigma), CFTR (clone MM13-4
or M3A7, 1:100; Merck Millipore, Spain), E-CAD (1:200, rabbit;
Cell Signaling Technology), SOX9 (1:100, goat; R&D Systems, UK),
Villin (1:100, goat; Santa Cruz Biotechnology, USA), FOXA2
(1:100, goat IgG; Santa Cruz Biotechnology, USA), CDX2 (1:100,
mouse IgG; DCS ImmunoLine, Germany), and GATA4 (1:300,
mouse IgG; Santa Cruz Biotechnology, USA). After permeabilization
in 0.2% Triton X-100/100 mM glycine/PBS buffer for 30 min at room
temperature (RT), cells were blocked with 5% BSA in PBS for 1 h at
RT. Cells were incubated with primary antibodies overnight at 4C in
2% BSA in PBS, followed by three washing steps with PBS. Alexa
Fluor 555 (1:500, donkey anti-mouse IgG or donkey anti-rabbit
IgG; Invitrogen, USA), Alexa Fluor 546 (1:500, donkey anti-goat
IgG; Invitrogen, USA), and Alexa Fluor 488 (1:500, donkey anti-
mouse IgG, donkey anti-rabbit IgG, or donkey anti-rat IgG; Invitro-
gen, USA) were used as secondary antibodies, incubated 1 h at RT
with 2% BSA in PBS. After washing with PBS, cells were stained868 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2with 40,6-diamidino-2-phenylindole (DAPI; 5 min, 1 mg/mL), washed
three times, and mounted with Dako fluorescent-mounting medium.Western Blot Analysis
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
(150 mM NaCl, 1% [v/v] Nonidet P-40 [NP-40], 1% [w/v] SDS,
and 50 mM Tris HCl, pH 8.0) in the presence of protease inhibitor
cocktail (P8340; Sigma, Spain), incubated for 30 min at 37C, and
passed through a 22G needle to reduce viscosity. Protein samples
were quantified by a modified Lowry method, and 70 mg of total pro-
tein diluted 1:1 in sample buffer (100 mMTris HCl, 10% [v/v] b-mer-
captoethanol, 4% [w/v] SDS, 0.02% [w/v] bromophenol blue, and
20% [v/v] glycerol) was separated on an 8% SDS-PAGE. Proteins
were transferred to a polyvinylidene fluoride (PVDF) membrane,
following a wet transfer standard protocol. Membrane was blocked
with 5% (w/v) skim milk in Tris-buffered saline (TBS)-Tween
(TBST) for 1 h at RT, washed three times with TBST, and incubated
overnight at 4C with a cocktail of three primary CFTR antibodies:
anti-CFTR monoclonal antibody (mAb) 450 (R-domain 696–705
aa), anti-CFTR mAb 570 (R-domain 731–742 aa), and anti-CFTR
mAb 596 (nucleotide-binding domain 2 [NBD2] 1204–1211 aa)
(Cystic Fibrosis Foundation, https://www.cff.org), diluted 1:500 in
TBST 2% (w/v) skim milk. Membrane was washed and incubated
1 h at RT in the dark with the secondary antibody (Thermo Scientific,
Spain) in TBST 2% (w/v) skim milk. After repeated washes, mem-
brane was developed using SuperSignal West Pico PLUS Chemilumi-
nescent Substrate (Thermo Scientific, Spain). As an internal loading
control, a-tubulin (Sigma, Spain) was used.Karyotyping
A standard optimized G-banding technique with minor modifica-
tions was employed to determine the karyotype of iPSC lines. Briefly,
actively proliferating cells were treated with 10 mg/mL Colcemid
(Sigma, Spain) for 3 h, trypsinized, washed in PBS, and incubated
in hypotonic PBS (74.85 mOsm/kg H2O) for 20 min, before
immersing them in Carnoy’s fixative (cold methanol/acetic acid 3:1;
both from BDH) for 30 min. Nuclei were then centrifuged at 500 
g for 2 min and resuspended in fresh Carnoy’s to wash residual
PBS. Fixed nuclei were spread and Gbanded by Biobanco del Sistema
Sanitario Público de Andalucía, Granada (Spain).Array CGH Analysis
Array CGH analysis was performed by Genetadi Biotech (Spain).
Genomic DNA was isolated from repaired and nonrepaired CF-hu-
man iPSC (hiPSC) and from parental fibroblasts by standard tech-
niques. Whole-genome array CGH analysis was carried out using
0.5 mg of genomic DNA and a 60-K oligonucleotide array (Agilent
Technologies, Santa Clara, USA; G4450A), according to the manufac-
turer’s instructions. Image quantification, hybridization quality con-
trol, and CNV detection were accomplished using Agilent Feature
Extraction version (v.)11.5 and AgilentWorkbench v.7.0. CNVs iden-
tified in the samples were visualized using the University of Califor-
nia, Santa Cruz (UCSC), Genome Browser (http://genome.ucsc.edu).020
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